SK17502000A3 - Polypeptid udskho protenu c - Google Patents

Polypeptid udskho protenu c Download PDF

Info

Publication number: SK17502000A3
Authority: SK; Slovakia
Prior art keywords: protein; polypeptide; apc; human protein; heavy chain
Prior art date: 1998-06-01

Application number

SK1750-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Lihua Huang

Ralph Meridith Riggin

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-01

Filing date

1999-06-01

Publication date

2001-09-11

1999-06-01 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2001-09-11 Publication of SK17502000A3 publication Critical patent/SK17502000A3/sk

Links

101500025568 Homo sapiens Saposin-D Proteins 0.000 title claims abstract description 35
208000007536 Thrombosis Diseases 0.000 claims abstract description 19
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 15
229920001184 polypeptide Polymers 0.000 claims abstract description 13
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
208000035475 disorder Diseases 0.000 claims abstract description 6
230000002792 vascular Effects 0.000 claims abstract description 5
101800004937 Protein C Proteins 0.000 claims description 34
101800001700 Saposin-D Proteins 0.000 claims description 34
238000000034 method Methods 0.000 claims description 13
102000053602 DNA Human genes 0.000 claims description 4
206010020608 Hypercoagulation Diseases 0.000 claims description 3
108020004511 Recombinant DNA Proteins 0.000 claims description 3
230000003027 hypercoagulation Effects 0.000 claims description 3
239000013598 vector Substances 0.000 claims description 3
108020004707 nucleic acids Proteins 0.000 claims 2
102000039446 nucleic acids Human genes 0.000 claims 2
150000007523 nucleic acids Chemical class 0.000 claims 2
102400000827 Saposin-D Human genes 0.000 claims 1
229940100689 human protein c Drugs 0.000 abstract description 23
230000004071 biological effect Effects 0.000 abstract description 2
201000005665 thrombophilia Diseases 0.000 abstract 1
229960000856 protein c Drugs 0.000 description 31
102000017975 Protein C Human genes 0.000 description 30
239000000243 solution Substances 0.000 description 26
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
108090000190 Thrombin Proteins 0.000 description 19
229960004072 thrombin Drugs 0.000 description 19
239000007983 Tris buffer Substances 0.000 description 18
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 12
239000011347 resin Substances 0.000 description 12
229920005989 resin Polymers 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
230000004913 activation Effects 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
102000010911 Enzyme Precursors Human genes 0.000 description 8
108010062466 Enzyme Precursors Proteins 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 7
239000000523 sample Substances 0.000 description 7
239000000872 buffer Substances 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000012488 sample solution Substances 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 5
150000001450 anions Chemical class 0.000 description 5
239000003814 drug Substances 0.000 description 5
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 5
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
206010040047 Sepsis Diseases 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
239000003146 anticoagulant agent Substances 0.000 description 4
238000003556 assay Methods 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000011575 calcium Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
206010053567 Coagulopathies Diseases 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
201000005660 Protein C Deficiency Diseases 0.000 description 3
108010000499 Thromboplastin Proteins 0.000 description 3
102000002262 Thromboplastin Human genes 0.000 description 3
230000003024 amidolytic effect Effects 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
230000035602 clotting Effects 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000010828 elution Methods 0.000 description 3
239000006167 equilibration buffer Substances 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 3
230000014508 negative regulation of coagulation Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
230000028327 secretion Effects 0.000 description 3
-1 sodium nitride Chemical class 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
101150020229 Apcs gene Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 2
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
208000002903 Thalassemia Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
208000028227 Viral hemorrhagic fever Diseases 0.000 description 2
229930003448 Vitamin K Natural products 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
235000019168 vitamin K Nutrition 0.000 description 2
239000011712 vitamin K Substances 0.000 description 2
150000003721 vitamin K derivatives Chemical class 0.000 description 2
229940046010 vitamin k Drugs 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
208000037157 Azotemia Diseases 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
206010058279 Factor V Leiden mutation Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
108700002232 Immediate-Early Genes Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
102000012607 Thrombomodulin Human genes 0.000 description 1
108010079274 Thrombomodulin Proteins 0.000 description 1
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
229940019700 blood coagulation factors Drugs 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000000058 esterolytic effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical group OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000019 pro-fibrinolytic effect Effects 0.000 description 1
108010074602 protein C propeptide Proteins 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
201000005380 purpura fulminans Diseases 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002446 thrombocytic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000007631 vascular surgery Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Hematology (AREA)
Biophysics (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1750-2000A 1998-06-01 1999-06-01 Polypeptid udskho protenu c SK17502000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8758598P	1998-06-01	1998-06-01
PCT/US1999/011969 WO1999063070A1 (fr)	1998-06-01	1999-06-01	Polypeptide de proteine c

Publications (1)

Publication Number	Publication Date
SK17502000A3 true SK17502000A3 (sk)	2001-09-11

Family

ID=22206075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1750-2000A SK17502000A3 (sk)	1998-06-01	1999-06-01	Polypeptid udskho protenu c

Country Status (25)

Country	Link
US (1)	US20040038288A1 (fr)
EP (1)	EP1084235A4 (fr)
JP (1)	JP2002517191A (fr)
KR (1)	KR20010043941A (fr)
CN (1)	CN1303428A (fr)
AR (1)	AR020082A1 (fr)
AU (1)	AU4409399A (fr)
BR (1)	BR9910858A (fr)
CA (1)	CA2330171A1 (fr)
CO (1)	CO5070672A1 (fr)
DZ (1)	DZ2803A1 (fr)
EA (1)	EA200001254A1 (fr)
HR (1)	HRP20000826A2 (fr)
HU (1)	HUP0102014A3 (fr)
ID (1)	ID27282A (fr)
IL (1)	IL139595A0 (fr)
NO (1)	NO20006091L (fr)
NZ (1)	NZ507982A (fr)
PE (1)	PE20000561A1 (fr)
PL (1)	PL344349A1 (fr)
SK (1)	SK17502000A3 (fr)
SV (1)	SV1999000067A (fr)
TR (1)	TR200003552T2 (fr)
WO (1)	WO1999063070A1 (fr)
ZA (1)	ZA200006647B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006025995A2 (fr) *	2004-07-27	2006-03-09	The Regents Of The University Of California	Compositions et methodes faisant intervenir des mutants md-2 et des proteines chimeres
CN108159399B (zh) *	2017-12-29	2020-07-24	华中科技大学同济医学院附属同济医院	一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2728240B2 (ja) *	1988-07-26	1998-03-18	ヘキスト薬品工業株式会社	ヒトプロテインｃ変異体及びその製造方法
ES2113878T3 (es) *	1989-12-29	1998-05-16	Zymogenetics Inc	Proteina c hibrida.
WO1991012320A1 (fr) *	1990-02-09	1991-08-22	Zymogenetics, Inc.	Proteine c activee a chaine legere tronquee
JPH0564588A (ja) *	1991-08-14	1993-03-19	Teijin Ltd	短い重鎖を有するヒトプロテインｃおよび活性化ヒトプロテインｃ

1999
- 1999-05-28 SV SV1999000067A patent/SV1999000067A/es not_active Application Discontinuation
- 1999-05-31 AR ARP990102575A patent/AR020082A1/es not_active Application Discontinuation
- 1999-06-01 CA CA002330171A patent/CA2330171A1/fr not_active Abandoned
- 1999-06-01 TR TR2000/03552T patent/TR200003552T2/xx unknown
- 1999-06-01 KR KR1020007013511A patent/KR20010043941A/ko not_active Withdrawn
- 1999-06-01 HR HR20000826A patent/HRP20000826A2/hr not_active Application Discontinuation
- 1999-06-01 PE PE1999000461A patent/PE20000561A1/es not_active Application Discontinuation
- 1999-06-01 HU HU0102014A patent/HUP0102014A3/hu unknown
- 1999-06-01 CO CO99034013A patent/CO5070672A1/es unknown
- 1999-06-01 BR BR9910858-5A patent/BR9910858A/pt not_active IP Right Cessation
- 1999-06-01 PL PL99344349A patent/PL344349A1/xx not_active Application Discontinuation
- 1999-06-01 EA EA200001254A patent/EA200001254A1/ru unknown
- 1999-06-01 NZ NZ507982A patent/NZ507982A/en not_active Application Discontinuation
- 1999-06-01 JP JP2000552266A patent/JP2002517191A/ja not_active Withdrawn
- 1999-06-01 DZ DZ990103A patent/DZ2803A1/fr active
- 1999-06-01 EP EP99927111A patent/EP1084235A4/fr not_active Withdrawn
- 1999-06-01 SK SK1750-2000A patent/SK17502000A3/sk unknown
- 1999-06-01 AU AU44093/99A patent/AU4409399A/en not_active Abandoned
- 1999-06-01 WO PCT/US1999/011969 patent/WO1999063070A1/fr not_active Ceased
- 1999-06-01 IL IL13959599A patent/IL139595A0/xx unknown
- 1999-06-01 ID IDW20002430A patent/ID27282A/id unknown
- 1999-06-01 CN CN99806859A patent/CN1303428A/zh active Pending
2000
- 2000-11-15 ZA ZA200006647A patent/ZA200006647B/en unknown
- 2000-11-30 NO NO20006091A patent/NO20006091L/no not_active Application Discontinuation
2003
- 2003-09-25 US US10/670,628 patent/US20040038288A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0102014A2 (hu)	2001-10-28
EP1084235A1 (fr)	2001-03-21
HUP0102014A3 (en)	2003-09-29
CO5070672A1 (es)	2001-08-28
PL344349A1 (en)	2001-11-05
EA200001254A1 (ru)	2001-06-25
US20040038288A1 (en)	2004-02-26
TR200003552T2 (tr)	2001-05-21
DZ2803A1 (fr)	2003-12-01
CN1303428A (zh)	2001-07-11
ZA200006647B (en)	2001-11-15
WO1999063070A1 (fr)	1999-12-09
NO20006091L (no)	2001-01-31
KR20010043941A (ko)	2001-05-25
AU4409399A (en)	1999-12-20
NZ507982A (en)	2004-01-30
SV1999000067A (es)	2000-07-06
EP1084235A4 (fr)	2002-03-27
IL139595A0 (en)	2002-02-10
JP2002517191A (ja)	2002-06-18
HRP20000826A2 (en)	2001-10-31
AR020082A1 (es)	2002-04-10
ID27282A (id)	2001-03-22
BR9910858A (pt)	2001-03-06
CA2330171A1 (fr)	1999-12-09
NO20006091D0 (no)	2000-11-30
PE20000561A1 (es)	2000-07-22

Publication	Publication Date	Title
US6162629A (en)	2000-12-19	Methods for processing activated protein C
CZ286016B6 (cs)	1999-12-15	Derivát lidské bílkoviny C, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
CZ253395A3 (en)	1996-01-17	Method of controlled activation and degradation of factor vii during purification process
JP3004375B2 (ja)	2000-01-31	ヒトプロテインｃのグリコシル化突然変異体の発現のためのベクターおよび化合物
CN112126636A (zh)	2020-12-25	一种高活性凝血因子XI突变体Ala570Thr
JPH10509436A (ja)	1998-09-14	被阻害形態の被活性化血液因子の生成方法
TW201431876A (zh)	2014-08-16	短－作用因子ｖｉｉ多肽類
SK17502000A3 (sk)	2001-09-11	Polypeptid udskho protenu c
RU2167936C2 (ru)	2001-05-27	Способ минимизации деградации активированного протеина с (варианты), стабилизированная композиция активированного протеина с
JP2003514545A (ja)	2003-04-22	プロテインｃ誘導体
CZ20004422A3 (cs)	2001-05-16	Polypeptid lidský protein C
MXPA00011807A (en)	2001-09-07	Human protein c polypeptide
AU2003252774A1 (en)	2003-11-06	Human Protein C Polypeptide
AU769144B2 (en)	2004-01-15	Improved methods for processing activated protein C
CN109415713A (zh)	2019-03-01	因子x变体
EP1557463A1 (fr)	2005-07-27	Méthodes améliorées de traitement de protéine C activée
CZ373799A3 (cs)	2000-06-14	Zlepšené způsoby zpracování aktivovaného proteinu C
HK1242733A1 (en)	2018-06-29	Short-acting factor vii polypeptides
MXPA99007817A (en)	2001-05-17	Factor x deletion mutants and analogues thereof